tumor tissue; adjacent non-tumor tissue; plasma
MDA-MB-231; MCF-7; MDA-MB-415; T47D; ZR-75-1; BT474; AU565; SK-BR-3; HCC1143; CAL51; BT549; HCC70; MCF-10A
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ERK (promotes); PI3K/AKT (promotes); ceRNA regulation (promotes)
RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Western Blot; In Vivo Animal Model; H&E Staining; Clinical Sample Validation; ROC Analysis; RNA-seq; Bioinformatics Analysis
circ_0042881 was elevated in BC tissues and plasma, associated with clinicopathological features, and showed diagnostic value by ROC (AUC = 0.802)
circ_0042881 (circNF1) is upregulated in breast cancer tissues and plasma and promotes proliferation, migration, invasion, tumor growth, and lung metastasis. It mainly localizes to the cytoplasm and acts as a ceRNA by sponging miR-217 to upregulate SOS1, thereby activating RAS and downstream MEK/ERK and PI3K/AKT signaling; EIF4A3 enhances its biogenesis.
0.8711
EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217/SOS1 axis to facilitate breast cancer progression.
combined biological and clinical study